Journal article

The role of hepatitis B surface antibodies in HBV infection, disease and clearance

Nadia Warner, Stephen Locarnini, Hui Xu

FUTURE VIROLOGY | FUTURE MEDICINE LTD | Published : 2020

Abstract

The clinical sequelae associated with chronic HBV infection is generally regarded as a consequence of an inadequate and inappropriate immune response to active viral replication, predominantly at the T-cell level. However, recent studies on hepatitis B surface antigen (HBsAg)-specific B cells and hepatitis B surface antibody (anti-HB) responses have identified their previously unrecognized role in the pathogenesis of chronic hepatitis B (CHB). These studies have also uncovered novel therapeutic approaches to more effectively target HBsAg loss and seroconversion, an important end point and regarded as a functional cure. Anti-HBs IgG has also been shown to have multiple direct acting antiviral..

View full abstract

Grants

Awarded by NHMRC Grant


Funding Acknowledgements

This work was partly supported by NHMRC Grant, project number APP1127538. S Locarnini receives consulting fees from Gilead Sciences, Biotron and Clear-B Pty Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.